Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 36.81 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 33.08 | Oscillator | Neutral |
| Williams %R (14) | -47.57 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.50 (Hist 0.04) | Oscillator | Buy |
| Average Directional Index (14) | 34.59 (+DI 18.1 / -DI 27.6) | Trend | Strong Sell |
Current price $11.79
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| EMA 20 | 12.04 | MA | Sell |
| SMA 20 | 12.01 | MA | Sell |
| EMA 50 | 12.86 | MA | Strong Sell |
| SMA 50 | 13.15 | MA | Strong Sell |
| SMA 200 | 14.39 | MA | Strong Sell |
| Jun 25, 25 |
| Goldman Sachs |
| maintain |
| Sell |
| Sell |
| Apr 17, 25 | Goldman Sachs | maintain | Sell | Sell |
| Oct 25, 23 | Jefferies | downgrade | Buy | Hold |
| Jul 20, 23 | Goldman Sachs | maintain | Sell | Sell |
| Jul 19, 23 | Northland Capital Markets | maintain | Market Perform | Market Perform |
| Jan 6, 23 | Jefferies | upgrade | Hold | Buy |
| Oct 19, 22 | SVB Leerink | maintain | Market Perform | Market Perform |
| May 24, 22 | Goldman Sachs | maintain | Sell | Sell |
| May 6, 22 | JP Morgan | downgrade | Neutral | Underweight |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Aug 1, 26 | Fishman Peter L. | officer: SVP, CFO | M-Exempt | 313 | — |
| Aug 1, 26 |
| Fishman Peter L. |
| officer: SVP, CFO |
| F-InKind |
| 155 @ $14.26 |
| $2.21K |
| Aug 1, 26 | Fishman Peter L. | officer: SVP, CFO | A-Award | 313 | — |
| Jul 1, 26 | Fishman Peter L. | officer: SVP, CFO | M-Exempt | 2,447 | — |
| Jul 1, 26 | Fishman Peter L. | officer: SVP, CFO | F-InKind | 1,206 @ $15.94 | $19.22K |
| Jul 1, 26 | Fishman Peter L. | officer: SVP, CFO | A-Award | 2,447 | — |
| Jul 1, 26 | Keenan David Paul | officer: EVP, Chief Operating Officer | M-Exempt | 3,688 | — |
| Jul 1, 26 | Keenan David Paul | officer: EVP, Chief Operating Officer | F-InKind | 1,926 @ $15.94 | $30.70K |
TTM vs. 5-year historical average (annual ratios)
| Metric | AMRN | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -8.3x | 30.4x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -19.7x | EPS est. -0.60 | Elevated |
| Price / Book | 0.6x | 0.9x | Discount |
| Price / Sales | 1.3x | 1.4x | In line |
| EV / EBITDA | -5.4x | 13.3x | Discount |
| Return on equity | -6.0% | — | Weak |
| Gross margin | 41.6% | 58.2% | Below hist. |
| Debt / Equity | 0.01 | 0.02 | Conservative |
| Piotroski / Altman Z | 3/9 | Z -2.05 | Distress |
Discounted cash flow model
Stock news · updated daily
DUBLIN and BRIDGEWATER, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that it will report third quarter 2026 financial results and conduct a conference call on Wednesday, October 28, 2026.
Amarin (NASDAQ: AMRN - Get Free Report) and SCYNEXIS (NASDAQ: SCYX - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, earnings, risk and institutional ownership. Institutional and Insider Ownership 22.3% of Amarin shares are
Elanco Animal Health (NYSE: ELAN - Get Free Report) and Amarin (NASDAQ: AMRN - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings. Volatility and Risk Elanco Animal Health has a
Here is how Amarin (AMRN) and Royalty Pharma (RPRX) have performed compared to their sector so far this year.
Presentations Expand Understanding of Treatment Adherence, Long-Term Outcomes, Lipoprotein(a), Coagulation Biomarkers, and Potential Mechanisms of Eicosapentaenoic Acid (EPA)
DUBLIN and BRIDGEWATER, N.J., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today highlighted a new post hoc analysis from the landmark REDUCE-IT® cardiovascular outcomes trial, presented at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany.
DUBLIN and BRIDGEWATER, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced upcoming presentations at the European Society of Cardiology (ESC) Congress 2026, August 28t h - 31st, in Munich, Germany.
Amarin Corporation plc (AMRN) Q2 2026 Earnings Call Transcript
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Jul 29, 2026 | -0.01 | -0.02 | Miss -100.0% | $42.21M |
| Apr 29, 2026 | 0.01 | -0.09 | Miss -1000.0% | $45.13M |
| Feb 25, 2026 | 0.07 | 0.01 | Miss -85.7% | $49.22M |
| Oct 29, 2025 | 0.08 | 0.01 | Miss -87.5% | $49.67M |
| Jul 30, 2025 | -0.66 | -0.03 | Beat 95.5% | $72.74M |
| May 7, 2025 | -1.12 | -0.04 | Beat 96.4% | $41.03M |
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| SC 13D/A | Aug 27, 2026 | 2026-08-27 18:56:43 | View |
| 4 | Aug 3, 2026 | 2026-08-03 16:30:24 | View |
| 10-Q | Jul 29, 2026 | 2026-07-29 16:30:39 | View |
| 8-K | Jul 29, 2026 | 2026-07-29 16:30:15 | View |
| 4 | Jul 15, 2026 | 2026-07-15 17:00:14 | View |
| 4 | Jul 15, 2026 | 2026-07-15 17:00:12 | View |
| 4 | Jul 15, 2026 | 2026-07-15 17:00:09 | View |
| 4 | Jul 15, 2026 | 2026-07-15 17:00:07 | View |
| 4 | Jun 30, 2026 | 2026-06-30 17:20:06 | View |
| 8-K | May 15, 2026 | 2026-05-14 21:30:16 | View |
Proxy statement (DEF 14A) disclosures